Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Effect of Left Ventricular Systolic Dysfunction on Response to Warfarin.

Ather S, Shendre A, Beasley TM, Brown T, Hill CE, Prabhu SD, Limdi NA.

Am J Cardiol. 2016 Jul 15;118(2):232-6. doi: 10.1016/j.amjcard.2016.04.047. Epub 2016 May 5.

PMID:
27241839
2.

Evaluation the frequency of factor V Leiden mutation in pregnant women with preeclampsia syndrome in an Iranian population.

Karimi S, Yavarian M, Azinfar A, Rajaei M, Azizi Kootenaee M.

Iran J Reprod Med. 2012 Jan;10(1):59-66.

3.

Influence of regular physical activity on warfarin dose and risk of hemorrhagic complications.

Shendre A, Beasley TM, Brown TM, Hill CE, Arnett DK, Limdi NA.

Pharmacotherapy. 2014 Jun;34(6):545-54.

4.

Epidemiology of activated protein C resistance and factor v leiden mutation in the mediterranean region.

Jadaon MM.

Mediterr J Hematol Infect Dis. 2011;3:e2011037. doi: 10.4084/MJHID.2011.037. Epub 2011 Sep 8.

5.

Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans.

Limdi N, Goldstein J, Blaisdell J, Beasley T, Rivers C, Acton R.

Per Med. 2007 May 1;4(2):157-169.

6.

Thrombotic genetic risk factors and warfarin pharmacogenetic variants in São Miguel's healthy population (Azores).

Branco CC, Pereirinha T, Cabral R, Pacheco PR, Mota-Vieira L.

Thromb J. 2009 Jun 18;7:9. doi: 10.1186/1477-9560-7-9.

7.

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.

Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM.

Blood Cells Mol Dis. 2009 Jul-Aug;43(1):119-28. doi: 10.1016/j.bcmd.2009.01.019. Epub 2009 Mar 17.

8.

Kidney function influences warfarin responsiveness and hemorrhagic complications.

Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, Acton RT, Allon M.

J Am Soc Nephrol. 2009 Apr;20(4):912-21. doi: 10.1681/ASN.2008070802. Epub 2009 Feb 18.

9.

VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.

Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N.

Pharmacogenomics. 2008 Oct;9(10):1445-58. doi: 10.2217/14622416.9.10.1445.

10.

Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.

Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, Acton RT.

Pharmacogenomics. 2008 May;9(5):511-26. doi: 10.2217/14622416.9.5.511.

Supplemental Content

Support Center